Roble Belko & Company’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $21K | Hold |
428
| – | – | ﹤0.01% | 273 |
|
|
2026
Q1 | $16K | Sell |
428
-464
| -52% | -$22K | ﹤0.01% | 276 |
|
|
2025
Q4 | $45K | Buy |
892
+434
| +95% | +$22.2K | 0.01% | 218 |
|
|
2025
Q3 | $25K | Buy |
458
+25
| +6% | +$1.46K | ﹤0.01% | 220 |
|
|
2025
Q2 | $30K | Hold |
433
| – | – | ﹤0.01% | 208 |
|
|
2025
Q1 | $30K | Hold |
433
| – | – | ﹤0.01% | 201 |
|
|
2024
Q4 | $37K | Hold |
433
| – | – | 0.01% | 185 |
|
|
2024
Q3 | $52K | Buy |
433
+1
| +0.2% | +$133 | 0.01% | 165 |
|
|
2024
Q2 | $62K | Hold |
432
| – | – | 0.01% | 160 |
|
|
2024
Q1 | $55K | Buy |
432
+6
| +1% | +$714 | 0.01% | 169 |
|
|
2023
Q4 | $44K | Hold |
426
| – | – | 0.01% | 166 |
|
|
2023
Q3 | $39K | Buy |
426
+4
| +0.9% | +$352 | 0.01% | 154 |
|
|
2023
Q2 | $34K | Hold |
422
| – | – | 0.01% | 160 |
|
|
2023
Q1 | $34K | Hold |
422
| – | – | 0.01% | 168 |
|
|
2022
Q4 | $29K | Hold |
422
| – | – | 0.01% | 186 |
|
|
2022
Q3 | $21K | Hold |
422
| – | – | 0.01% | 195 |
|
|
2022
Q2 | $24K | Hold |
422
| – | – | 0.01% | 187 |
|
|
2022
Q1 | $23K | Hold |
422
| – | – | ﹤0.01% | 225 |
|
|
2021
Q4 | $24K | Hold |
422
| – | – | ﹤0.01% | 203 |
|
|
2021
Q3 | $20K | Hold |
422
| – | – | ﹤0.01% | 206 |
|
|
2021
Q2 | $18K | Hold |
422
| – | – | ﹤0.01% | 226 |
|
|
2021
Q1 | $14K | Hold |
422
| – | – | ﹤0.01% | 237 |
|
|
2020
Q4 | $15K | Hold |
422
| – | – | ﹤0.01% | 212 |
|
|
2020
Q3 | $15K | Hold |
422
| – | – | ﹤0.01% | 207 |
|
|
2020
Q2 | $14K | Hold |
422
| – | – | ﹤0.01% | 223 |
|
|
2020
Q1 | $13K | Hold |
422
| – | – | ﹤0.01% | 227 |
|
|
2019
Q4 | $12K | Hold |
422
| – | – | ﹤0.01% | 251 |
|
|
2019
Q3 | $11K | Hold |
422
| – | – | ﹤0.01% | 253 |
|
|
2019
Q2 | $11K | Hold |
422
| – | – | ﹤0.01% | 250 |
|
|
2019
Q1 | $11K | Hold |
422
| – | – | ﹤0.01% | 219 |
|
|
2018
Q4 | $10K | Hold |
422
| – | – | ﹤0.01% | 209 |
|
|
2018
Q3 | $10K | Hold |
422
| – | – | ﹤0.01% | 224 |
|
|
2018
Q2 | $10K | Hold |
422
| – | – | ﹤0.01% | 229 |
|
|
2018
Q1 | $10K | Hold |
422
| – | – | ﹤0.01% | 234 |
|
|
2017
Q4 | $11K | Hold |
422
| – | – | ﹤0.01% | 215 |
|
|
2017
Q3 | $10K | Hold |
422
| – | – | ﹤0.01% | 190 |
|
|
2017
Q2 | $9K | Hold |
422
| – | – | ﹤0.01% | 200 |
|
|
2017
Q1 | $7K | Hold |
422
| – | – | ﹤0.01% | 236 |
|
|
2016
Q4 | $8K | Buy |
+422
| New | +$7.65K | ﹤0.01% | 233 |
|
Other funds holding NVO
F
Roble Belko & Company's NVO Position: Q2 2026 in Review
Roble Belko & Company held its Novo Nordisk (NVO) position steady in Q2 2026 at 428 shares worth $21K. The position accounts for ﹤0.01% of the portfolio, ranked #273.
Roble Belko & Company first reported a position in NVO in Q4 2016 and has held it in 39 quarters since. The position peaked at $62K in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.
- Roble Belko & Company held 428 shares of Novo Nordisk worth $21K as of Q2 2026.
- Roble Belko & Company left its Novo Nordisk share count unchanged in Q2 2026.
- Novo Nordisk made up ﹤0.01% of Roble Belko & Company's portfolio in Q2 2026, its #273 holding.
- Roble Belko & Company first reported a position in Novo Nordisk in Q4 2016 and has held it in 39 quarters since.
- Roble Belko & Company's Novo Nordisk position peaked at $62K in Q2 2024.
- 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.
Based on Roble Belko & Company's 13F filing for Q2 2026, filed 24 Jul 2026.